Last10K.com

Kura Oncology, Inc. (KURA) SEC Filing 8-K Material Event for the period ending Tuesday, March 5, 2019

Kura Oncology, Inc.

HISTORY TOOLS
CIK: 1422143 Ticker: KURA

View differences made from one to another to evaluate Kura Oncology, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Kura Oncology, Inc..

Continue

Assess how Kura Oncology, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Kura Oncology, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Material Contracts, Statements, Certifications & more

Kura Oncology, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 5.1: Opinion Regarding Legality
Exhibit 10.1: Material Contract
Ticker: KURA
CIK: 1422143
Form Type: 8-K Corporate News
Accession Number: 0001193125-19-064084
Submitted to the SEC: Tue Mar 05 2019 4:21:03 PM EST
Accepted by the SEC: Tue Mar 05 2019
Period: Tuesday, March 5, 2019
Industry: Pharmaceutical Preparations
Events:
  1. Financial Exhibit
  2. New Agreement

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/kura/0001193125-19-064084.htm